article thumbnail

Open Targets Platform 25.06 has been released!

The Open Targets Blog

The Platform does not have direct genetic evidence to link IFNAR1 to SLE, but there is an approved therapy, Anifrolumab, targeting IFNAR1 for SLE. Directionality annotations for pharmacogenetics data Pharmacogenetics widgets on the variant, target, and drug profile pages now have an additional Directionality column.

article thumbnail

Inside The Altascientist: Understanding Drug Interaction Factors for Safer, More Effective Therapies

Alta Sciences

In recent years, pharmacogenetics research has shown significant differences in the pharmacokinetics among Caucasians, African Americans, Hispanics, and Asians, or at individual levels by stratifying groups based on genetic analysis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Challenges and Solutions to Drug-Drug Interactions for Clinical Development

DrugBank

Conversely, drug combinations that reduce the effectiveness of essential therapies can lead to therapeutic failure. For instance, polymorphisms in CYP2C19 can cause poor or extensive metabolism of certain drugs, like clopidogrel , leading to either ineffective therapy or a heightened risk of adverse events.

article thumbnail

Integrating pharmacogenetics data: a new lens for target prioritisation

The Open Targets Blog

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.

article thumbnail

Factors influencing the Central Nervous System (CNS) distribution of the ATR inhibitor elimusertib (BAY1895344): Implications for the treatment of CNS tumors [Metabolism, Transport, and Pharmacogenetics]

ASPET

Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. Elimusertib, a novel ATR kinase inhibitor, can prevent repair of damaged DNA, increasing efficacy of DNA damaging cytotoxic therapies. Subsequent activation of DNA damage response (DDR) pathways can induce resistance.

article thumbnail

The Plasma Membrane Monoamine Transporter (PMAT) is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter [Metabolism, Transport, and Pharmacogenetics]

ASPET

131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy. Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients.

article thumbnail

CNS distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors [Metabolism, Transport, and Pharmacogenetics]

ASPET

With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB). Achieving adequate exposure of a therapeutic agent at the target is a critical determinant of efficacious chemotherapy.